Principal Investigator

Louis Gaboury

Histology and Molecular Pathology

Subscribe to the newsletter

After obtaining his doctoral degree in Medicine from the Université de Montréal in 1978, Dr. Louis Gaboury completed a training program in anatomic-pathology. Associate of the Royal College of Physicians and Surgeons of Canada, and holder of a Terry Fox scholarship from the National Cancer Institute of Canada, he continued his studies in experimental pathology in the Terry Fox Laboratory of the BC Cancer Research Centre (1983-1988) and obtained a Ph.D. from the University of British Columbia. From 1988 to 1991 he perfected his training in retrovirology and in molecular biology at the IRCM.

Currently a Professor in the Department of Pathology and Cellular Biology, he has been focusing on cancer since being named to the position. He has occupied several administrative functions including Director of the Department of Pathology of the CHUM (1997-2002), President of the Association des Pathologistes du Québec (2004-2011) and Director of the University Department of Pathology and Cell Biology. He has been in charge of the IRIC’s Histology Core Facility since 2006, and was named Principal Investigator at IRIC in 2009.

Principal Investigator, Histology and Molecular Pathology Research Unit, IRIC
Histology Core Facility Scientific Direction

Director, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal

Research unit on histology and molecular pathology

Marcelle-Coutu Pavilion, 3306-15

Phone (office)
(514) 343-6111, ext. 0413
Fax
(514) 343-7780
Email
louis.gaboury@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Histology and Molecular Pathology

Using microscopy, laser microdissection, immunohistochemistry, in situ hybridization, digitalization and image analysis techniques, Dr. Louis Gaboury and the members of his team seek to better characterize tumors and to understand each critical step involved with the development and progression of cancers. Over time, a greater understanding of tumor subtypes will lead to identifying new prognostic and predictive cancer markers.

Discover the research unit View the research team

Research topics

Publications

  • December 14, 2023

    The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.

    Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF
    Cell Rep 2023-12-14 ;42( 12 ):113604

  • December 11, 2023

    Silicone Particles in Capsules Around Breast Implants: An Investigation Into Currently Available Implants in North America.

    Danino MA, Dziubek M, Dalfen J, Bonapace-Potvin M, Gaboury L, Giot JP, Laurent R
    Aesthet Surg J 2023-12-11 ;

  • March 20, 2023

    Duplex Phenotype Detection and Targeting of Breast Cancer Cells Using Nanotube Nanoprobes and Raman Imaging.

    Mal S, Duarte E Souza L, Allard C, David C, Blais-Ouellette S, Gaboury L, Tang NY, Martel R
    ACS Appl Bio Mater 2023-03-20 ;6( 3 ):1173-1184

  • January 1, 2023

    Combined IFN-γ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.

    Joly JA, Vallée A, Bourdin B, Bourbonnais S, Patey N, Gaboury L, Théorêt Y, Decaluwe H
    J Allergy Clin Immunol 2023-01-01 ;151( 1 ):247-259.e7

  • See all publications

Awards and distinctions

  • Teaching Excellence Award, Faculty of Medicine, Université de Montréal, 1999